Publications by authors named "J J H Celestino"
Adult type ovarian granulosa cell tumors (AGCTs) are rare malignancies with the near universal c.C402G (p.Cys134Trp) somatic mutation in FOXL2, a Forkhead box-family transcription factor important for ovarian function.
View Article and Find Full Text PDFArticle Synopsis
- A study in the UK showed that using CA125 blood tests and ultrasound for ovarian cancer didn't really lower deaths but helped find earlier cases.
- Researchers tested blood samples from women with ovarian cancer and controls to create a new test using 7 specific chemicals plus CA125.
- This new test was better at finding early-stage ovarian cancer, catching a good number of cases even when CA125 levels were low.
Background: The efficacy and feasibility of pembrolizumab combined with chemotherapy in frontline management of advanced high-grade epithelial ovarian cancer (EOC) is unknown. Additionally, modification of the tumor microenvironment following neoadjuvant therapy is not well understood.
Methods: In this single-arm phase 2 trial (this study was registered at ClinicalTrials.
Evaluation of the morphology and development of preantral ovarian follicles in mice submitted to a chronic diet of dietary supplementation with leaves.
Alesandro Silva Ferreira Francisco Glauber Peixoto Ferreira Etho Roberio Medeiros Nascimento Gildas Mbemya Tetaping Laritza Ferreira de Lima Juliana Jales de Hollanda Celestino
Anim Reprod
July 2024
Article Synopsis
- * The results showed no significant differences in the number of normal and developing follicles between the PAM treatments and control after both time periods, indicating that PAM did not harm reproductive health.
- * However, after 90 days, only the 5% PAM treatment affected the ovarian stromal cell density, suggesting minor impacts at this concentration, but overall, the study concluded that PAM supplementation was safe for animal consumption.
Article Synopsis
- Nonsurgical treatments like the levonorgestrel intrauterine device (LIUD) are being explored for managing endometrial atypical hyperplasia (AH) and endometrioid endometrial cancer (EEC), highlighting a need for long-term efficacy data.
- In a study of 43 patients initially responding to LIUD, 39% relapsed, with significant factors for shorter duration of response including younger age and lack of response at the 6-month mark.
- Molecular analysis during the study revealed changes in immune cell populations and pathways involved in relapse, suggesting immune mechanisms play a crucial role in the treatment's effectiveness.